Currently out of the existing stock ratings of Tim Lugo, 32 are a BUY (80%), 8 are a HOLD (20%).

Tim Lugo

Work Performance Price Targets & Ratings Chart

Analyst Tim Lugo, carries an average stock price target met ratio of 60.61% that have a potential upside of 48.08% achieved within 692 days. Previously, Tim Lugo worked at WILLIAM BLAIR.

Tim Lugo’s has documented 68 price targets and ratings displayed on 20 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RVNC, Revance The at 12-Aug-2024.

Wall Street Analyst Tim Lugo

Analyst best performing recommendations are on EGRX (EAGLE PHARMACEUTICALS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 3/20/2013. The price target of $52 was fulfilled within 198 days with a profit of $19.23 (58.68%) receiving and performance score of 2.96.

Average potential price target upside

of $29.1 (74.63%) on SRPT (SAREPTA THERAPEUTICS).
of $21.19 (23.79%) on BMRN (BIOMARIN PHARMACEUTICAL).
of $8.58 (33.07%) on ADMS (ADAMAS PHARMACEUTICALS).

SRPT Sarepta Therapeutics ALBO Albireo Pharma AVIR Atea Pharmaceuticals BBI Brickell Biotech EGRX Eagle Pharmaceuticals ADMS Adamas Pharmaceuticals ALLK Allakos BMRN Biomarin Pharmaceutical KNTE Kinnate Biopharma VTGN VistaGen Therapeutics RVNC Revance The XENE Xenon Pharmaceuticals ZGNX Zogenix TVTX Travere Therapeutics ABBV AbbVie COLL Collegium Pharmaceutical NMTR 9 Meters Biopharma EYEN Eyenovia SPRY ARS Pharmaceuticals SAGE Sage Therapeutic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gil Blum (NEEDHAM)